Literature DB >> 12148725

A comparison of physically and radiobiologically based optimization for IMRT.

Lois Jones1, Peter Hoban.   

Abstract

Many optimization techniques for intensity modulated radiotherapy have now been developed. The majority of these techniques including all the commercial systems that are available are based on physical dose methods of assessment. Some techniques have also been based on radiobiological models. None of the radiobiological optimization techniques however have assessed the clinically realistic situation of considering both tumor and normal cells within the target volume. This study considers a ratio-based fluence optimizing technique to compare a dose-based optimization method described previously and two biologically based models. The biologically based methods use the values of equivalent uniform dose calculated for the tumor cells and integral biological effective dose for normal cells. The first biologically based method includes only tumor cells in the target volume while the second considers both tumor and normal cells in the target volume. All three methods achieve good conformation to the target volume. The biologically based optimization without the normal tissue in the target volume shows a high dose region in the center of the target volume while this is reduced when the normal tissues are also considered in the target volume. This effect occurs because the normal tissues in the target volume require the optimization to reduce the dose and therefore limit the maximum dose to that volume.

Entities:  

Mesh:

Year:  2002        PMID: 12148725     DOI: 10.1118/1.1487420

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  1 in total

Review 1.  Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?

Authors:  Marco D'Andrea; Silvia Strolin; Sara Ungania; Alessandra Cacciatore; Vicente Bruzzaniti; Raffaella Marconi; Marcello Benassi; Lidia Strigari
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.